BioCentury | Jan 15, 2015
Distillery Therapeutics

Therapeutics: P. falciparum P-type cation-transporter ATPase 4 (PfATP4)

...artesunate/amodiaquine, a fixed-dose combination of artesunate and amodiaquine, to treat malaria infection. GlaxoSmithKline plc markets Malarone...
BioCentury | Dec 19, 2013
Targets & Mechanisms

Lipid kinase enters the malaria stage

...for alternative discovery and development at GlaxoSmithKline plc 's malaria discovery performance unit. GSK markets Malarone...
BioCentury | Oct 10, 2011
Clinical News

Sevuparin/DF02: Phase I/II started

...Dilaforette began an open-label, dose-escalation, Thai Phase I/II trial to compare Malanil atovaquone/proguanil plus IV Sevuparin/DF02...
BioCentury | Nov 6, 2008
Distillery Techniques

Technology: Drug platforms

...genomes of additional P. vivax parasites from different geographic regions to identify sequence variation. Malarone atovaquone/proguanil...
BioCentury | Aug 14, 2008
Distillery Techniques

This Week in Techniques

...and developing a new adenovirus vector that can infect chimpanzees in vivo. GlaxoSmithKline plc's Malarone ^atovaquone/proguanil...
BioCentury | Jul 24, 2000
Clinical News

Malarone atovaquone/proguanil regulatory update

...The FDA granted marketing approval for Malarone, an oral fixed dosage combination of two previously approved...
...treat malaria in children and adults. Glaxo Wellcome plc (LSE:GLXO; GLX), London, U.K. Product: Malarone atovaquone/proguanil...
Items per page:
1 - 6 of 6